Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant toripalimab plus SABR in resectable NSCLC
ChiCTR2000029277Phase 2Recruiting
- Sponsor
- Jinling Hospital
- Start
- Oct 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Jinling Hospital. Primary endpoints: Safety and Pathologic response. Started Oct 2019; status: recruiting.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000029277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029277.